Correlation of fundus fluorescein angiography and spectral-domain optical coherence tomography in identification of membrane subtypes in neovascular age-related macular degeneration

Ophthalmologica. 2014;231(3):153-9. doi: 10.1159/000355091. Epub 2013 Nov 6.


Aims: To assess the sensitivity and specificity of spectral-domain optical coherence tomography (SDOCT) for the determination of choroidal neovascularization (CNV) subtypes in neovascular age-related macular degeneration (AMD) compared to fundus fluorescein angiography (FFA) and also the agreement between the two procedures.

Design: This was a retrospective, observational study.

Methods: We evaluated and compared the CNV subtypes on FFA and OCT in 100 eyes initiated on ranibizumab for neovascular AMD.

Results: SDOCT showed high sensitivity (85.7-98.3%) and specificity (84.2-100%) compared to FFA in the diagnosis of the CNV subtype. The area under the receiver-operating characteristic curve ranged from 0.9 to 0.93 (p value <0.0001) for the different CNV subtypes. Weighted kappa statistics showed a near-perfect agreement of 0.85 between the procedures.

Conclusion: SDOCT is a reliable tool for the diagnosis of CNV subtypes in neovascular AMD obviating the need for an invasive procedure such as FFA.

Publication types

  • Comparative Study
  • Observational Study

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Choroidal Neovascularization / classification
  • Choroidal Neovascularization / diagnosis*
  • Female
  • Fluorescein Angiography*
  • Fluorescent Dyes
  • Humans
  • Indocyanine Green
  • Male
  • Ranibizumab
  • Reproducibility of Results
  • Retrospective Studies
  • Sensitivity and Specificity
  • Tomography, Optical Coherence*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Wet Macular Degeneration / diagnosis*
  • Wet Macular Degeneration / drug therapy


  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Fluorescent Dyes
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Indocyanine Green
  • Ranibizumab